Navigation Links
Lilly Reports Second-Quarter 2011 Results
Date:7/21/2011

many of our marketed products, as well as important investments we are making to expand our commercial opportunities and deliver the next wave of potential new medicines to patients," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "Key Lilly products continue to perform well, including Cymbalta, Cialis and our insulins. Exchange rates have also contributed to favorable sales comparisons. At the same time, we are investing for the company's future by supporting the launches of new medicines and new indications, as well as funding our R&D pipeline, which now boasts 70 potential new medicines in clinical development."

Key Events Over the Last Three Months

  • The U.S. Food and Drug Administration (FDA) approved Tradjenta™ (linagliptin), a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The company, along with its partner Boehringer Ingelheim, recently launched Tradjenta in the United States. Linagliptin was also approved in Japan, Mexico and Brazil and received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
  • The European Commission granted marketing authorization to Bydureon™, the first once-weekly treatment for type 2 diabetes. The company is developing Bydureon along with its partners, Amylin Pharmaceuticals and Alkermes, Inc.
  • The company filed for a new indication with the FDA for Erbitux® in first-line non-small cell lung cancer.
  • The U.S. District Court for the Southern District of Indiana issued an order that prohibits the remaining defendants in the Cymbalta® patent litigation from selling a generic duloxetine product in the United States during the term of the Cymbalta compound patent. The patent provides protection for Cymbalta until at least June of 2013.  
  • The company signed agreements with private investors Care Capit
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
    2. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
    3. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
    4. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
    5. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
    6. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
    7. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
    8. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
    9. Lilly Declares Third-Quarter 2011 Dividend
    10. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
    11. Synthes and Lilly Sign Development and Collaboration Agreement
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... , May 22, 2015  Research and Benchmarking ... sixth Medical Affairs Roundtable on Thursday, ... a virtual roundtable to discuss "Medical Affairs, Role ... Best Practices, Medical Affairs Consortium provides Medical Affairs ... the key challenges they face. The consortium has ...
    (Date:5/22/2015)... 2015 /CNW/ - The Taskforce representing Canada,s ... the hard work that the Minister and Health Canada have ... program recognizes the needs of the thalidomide survivors, and more ... year, tax free, with annual adjustments for inflation. ... payments of $100,000 based on the severity of their disability, ...
    (Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
    Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
    ... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
    ... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
    Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
    (Date:5/22/2015)... “It’s like learning an new language,” ... President of Clinical Operations/Education and Training at Harmony ... how care is coded and reimbursed.” , Harmony ... reimbursement, operations and compliance consulting, as well as ... a new series of day-long seminars on the ...
    (Date:5/22/2015)... 2015 Coordinating care for people ... Historically providers have not been reimbursed or rewarded ... 2015, Medicare has paved the way by offering ... the launch of Oculus Health , an ... using the platform will now be able to ...
    (Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
    (Date:5/22/2015)... (PRWEB) May 22, 2015 According to ... hub for drug related death, totaling almost 2,500 confirmed drug ... reported by state officials, totals 2,489 deaths stemming from legal ... out, Pennsylvania loses seven people every day to fatal overdoses ... been singled out as one of the most rife with ...
    (Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
    Breaking Medicine News(10 mins):Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2
    ... percent; real number may be as low as 4 percent, ... new, closer look at data on Caesarean section births in ... surgical deliveries is far lower than previously thought. , When ... C-sections being performed in the United States on women who ...
    ... conducted by University of Denver (DU) Associate Professor Rene ... undergraduate students to wash their hands more frequently after ... researchers posted messages in the bathrooms of two DU ... on you, wash your hands" or "You just peed, ...
    ... , ... Phoenix, AZ (Vocus) December 23, 2008 -- Adding to a ... results released in the December 23rd issue of Circulation further emphasized the ... sedentary job structures most Americans fall far short of the minimum recommended ...
    ... and Translational Science (CCTS) has awarded 18 grants ... grant program. The grants, which range from $2,000 ... translational science that, if successful, might lead to ... funds from a 2006 Clinical and Translational Science ...
    ... Mixing prescription, nonprescription meds poses dangers, researchers say , , ... 4 percent of older adults in the United States ... put them at risk for potentially dangerous interactions, a ... adults over 65 account for more than 175,000 emergency ...
    ... Women who did weight-bearing sports such as swimming had greater ... News) -- Doing weight-bearing exercise during adolescence may help women ... says. , Published online Dec. 22 in the British ... conclusions by looking at the teenage exercise habits of 46 ...
    Cached Medicine News:Health News:Rate of Unnecessary C-Sections Far Lower Than Thought 2Health News:Rate of Unnecessary C-Sections Far Lower Than Thought 3Health News:University of Denver uses 'gross' messaging to increases handwashing, fight Norovirus 2Health News:Treadmill Desks to the Rescue: Weight Control and Activity Critical in Preventing Heart Failure 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 3Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 4Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4
    Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
    Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
    ... Standard/Conventional Blade. Stainless steel. Lamp supplied ... tradition of high quality standard incandescent ... blades have been continually refined through ... over to minimize maintenance requirements. They ...
    ... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
    Medicine Products: